Scarica l'app Stockscreener
192.67
0.79%
-1.53
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$194.20
Aprire:
$194.5
Volume 24 ore:
691.96K
Relative Volume:
0.69
Capitalizzazione di mercato:
$21.33B
Reddito:
$11.28B
Utile/perdita netta:
$1.07B
Rapporto P/E:
21.25
EPS:
9.0657
Flusso di cassa netto:
$1.33B
1 W Prestazione:
-1.83%
1M Prestazione:
-2.54%
6M Prestazione:
+9.50%
1 anno Prestazione:
+8.66%
Intervallo 1D:
$192.21
$196.34
Intervallo di 1 settimana:
$187.50
$198.78
Portata 52W:
$164.65
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
192.67 | 21.33B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
469.21 | 174.37B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
175.15 | 123.97B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.46 | 45.07B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.52 | 32.36B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
307.12 | 30.15B | 3.17B | 642.63M | 516.49M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Quest Diagnostics Incorporated $DGX Stock Holdings Increased by Artemis Investment Management LLP - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Short Interest Update - MarketBeat
[8-K] QUEST DIAGNOSTICS INC Reports Material Event - Stock Titan
Quest Diagnostics Incorporated $DGX Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Sold by Danica Pension Livsforsikringsaktieselskab - MarketBeat
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Vanguard reports 8.27M Quest Diagnostics shares (NYSE: DGX) stake - Stock Titan
Quest Diagnostics Inc (DGX) Stock Price & 30 Year Financial Data - GuruFocus
Quest Diagnostics Incorporated $DGX Shares Purchased by UBS Group AG - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Purchased by Vanguard Group Inc. - MarketBeat
Valmont Industries posts upbeat Q1 results, joins UnitedHealth Group, Quest Diagnostics and other big stocks moving higher on Tuesday - MSN
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Vanguard reports 6.10M-share stake in Quest Diagnostics (DGX) — 5.54% - Stock Titan
Quest Diagnostics (DGX) sells $500M 5.00% senior notes due 2036 at 98.751% - Stock Titan
BlackRock Systematic Multi-Strategy Fund's Quest Diagnostics Inc(DGX) Holding History - GuruFocus
Smart Money is Buying Quest Diagnostics Inc. (DGX) - The Acquirer's Multiple
Quest Diagnostics Inc (DGX) Stock Price, Trades & News - GuruFocus
Quest Diagnostics Incorporated (DGX) stock price, news, quote and history - Yahoo Finance Australia
Quest Diagnostics prices $500 million senior notes offering By Investing.com - Investing.com Canada
Quest Diagnostics prices $500M debt deal ahead of June note maturity - Stock Titan
DGX SEC FilingsQuest Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Quest Diagnostics Inc files for senior notes, size not disclosed - marketscreener.com
Quest Diagnostics (DGX) launches senior note offering; may repay $500M 2026 notes - Stock Titan
Evercore ISI Group Maintains Quest Diagnostics (DGX) In-Line Recommendation - MSN
Quest Diagnostics Incorporated $DGX Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
[Form 4] QUEST DIAGNOSTICS INC Insider Trading Activity - Stock Titan
Quest Diagnostics (DGX) SVP reports 49-share dividend reinvestment - Stock Titan
Quest Diagnostics (NYSE: DGX) director acquires shares through dividend reinvestment - Stock Titan
Dividend plan boosts Quest Diagnostics (NYSE: DGX) director stake - Stock Titan
Quest Diagnostics (DGX) director boosts holdings with small dividend reinvestment - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP reports small 39-share acquisition - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP adds 37 shares through dividend reinvestment - Stock Titan
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors - MarketWatch
Quest Diagnostics: Good Q1, Solid Business, Steady Share Price Upside Likely (NYSE:DGX) - Seeking Alpha
Copeland Capital Management LLC Cuts Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Stock Holdings Decreased by Cwm LLC - MarketBeat
These Companies Are Raising Guidance This Earnings Season - TradingView
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Quest Diagnostics (DGX) and Merck & Company (MRK) - The Globe and Mail
Zurcher Kantonalbank Zurich Cantonalbank Has $14.02 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (NYSE: DGX) boosts Q1 2026 earnings on 11% volume growth - Stock Titan
Quest Diagnostics deal helps push Secaucus office tower past 75% occupancy - Yahoo Finance
Quest Diagnostics Stock Gains 5% After Q1 Earnings Exceed Analyst Expectations - TIKR.com
Quest Diagnostics (NYSE:DGX) Price Target Raised to $229.00 - MarketBeat
Quest Diagnostics (NYSE:DGX) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Earnings - Benzinga
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock - Yahoo Finance
Truist Financial Forecasts Strong Price Appreciation for Quest Diagnostics (NYSE:DGX) Stock - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Q1 2026 Earnings Call Transcript - Insider Monkey
Evercore ISI Adjusts Price Target on Quest Diagnostics to $225 From $210, Maintains In Line Rating - marketscreener.com
Jefferies Adjusts Price Target on Quest Diagnostics to $225 From $220, Maintains Buy Rating - marketscreener.com
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Quest Diagnostics Inc Azioni (DGX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PREVOZNIK MICHAEL E | SVP & General Counsel |
Mar 05 '26 |
Sale |
206.21 |
3,878 |
799,682 |
37,557 |
| Plewman Patrick | SVP for Diagnostic Services |
Mar 05 '26 |
Sale |
206.21 |
2,855 |
588,730 |
15,198 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions |
Mar 04 '26 |
Sale |
204.86 |
2,628 |
538,372 |
13,441 |
0.37%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):